4-acetamidobenzoic acid;9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;1-(dimethylamino)propan-2-ol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 4-acetamidobenzoic acid;9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;1-(dimethylamino)propan-2-ol
• 化学式: C24H34N6O9
• 分子量: 550.6
• InChiKey: PBJNZCQJMWVIRT-ANEDODFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.0
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  219
• 氢给体数：
  7
• 氢受体数：
  11

文献信息

• Use of inosine for cancer immunotherapy
  申请人：IMMUNOSPARKLE BIOSCIENCE LLC

  公开号：US10736913B1

  公开（公告）日：2020-08-11

  Disclosed are formulations for the treatment of cancer including inosine or a related compound in combination with an immune checkpoint inhibitor including but not limited to immune checkpoint inhibitor binding agents (including anti-CTLA4, anti-PD1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-CD47, anti-VISTA, and anti-PD-L1), and optionally also including a reinforcing agent to boost immune response, including CAR-T, CAR-NK, tumor vaccine, oncolytic virus vaccine, TLR7/8 agonist, anti-CD47 or IL-2 receptor agonist, and optionally also including other pharmacologically immune-boosting active agents.

  所公开的是用于治疗癌症的制剂，包括肌苷或相关化合物与免疫检查点抑制剂（包括但不限于免疫检查点抑制剂结合剂（包括抗CTLA4、抗PD1、抗LAG-3、抗TIM-3、抗TIGIT、抗CD47、抗VISTA和抗PD-L1））的组合、T、CAR-NK、肿瘤疫苗、溶瘤病毒疫苗、TLR7/8 激动剂、抗-CD47 或 IL-2 受体激动剂，还可选择包括其他药理免疫增强活性剂。
• Specific binding agents to varicella-zoster virus and uses related thereto
  申请人：Emory University

  公开号：US11147870B2

  公开（公告）日：2021-10-19

  This disclosure relates to specific binding agents to varicella-zoster virus proteins or glycoproteins. In certain embodiments the specific binding agents are antibodies and binding fragments thereof disclosed herein. In certain embodiments, this disclosure relates to methods of treating or preventing a varicella-zoster infection comprising administering an effective amount of a specific binding agent disclosed herein to a subject in need thereof.

  本公开涉及与水痘-带状疱疹病毒蛋白或糖蛋白的特异性结合剂。在某些实施方案中，特异性结合剂是本文公开的抗体及其结合片段。在某些实施方案中，本公开涉及治疗或预防水痘-带状疱疹感染的方法，包括向有需要的受试者施用有效量的本文公开的特异性结合剂。
• Specific Binding Agents to Varicella-Zoster Virus and Uses Related Thereto
  申请人：Emory University

  公开号：US20190328867A1

  公开（公告）日：2019-10-31

  This disclosure relates to specific binding agents to varicella-zoster virus proteins or glycoproteins. In certain embodiments the specific binding agents are antibodies and binding fragments thereof disclosed herein. In certain embodiments, this disclosure relates to methods of treating or preventing a varicella-zoster infection comprising administering an effective amount of a specific binding agent disclosed herein to a subject in need thereof.
• [EN] USE OF INOSINE FOR CANCER IMMUNOTHERAPY<br/>[FR] UTILISATION DE L'INOSINE EN IMMUNOTHÉRAPIE ANTICANCÉREUSE
  申请人：IMMUNOSPARKLE BIOSCIENCE LLC

  公开号：WO2020197905A1

  公开（公告）日：2020-10-01

  Disclosed are formulations for the treatment of cancer including inosine or a related compound in combination with an immune checkpoint inhibitor including but not limited to immune checkpoint inhibitor binding agents (including anti-CTLA4, anti-PD1, anti-LAG-3, anti-TIM-3, anti-TIGIT, anti-CD47, anti-VISTA, and anti-PD-L1 ), and optionally also including a reinforcing agent to boost immune response, including CAR-T, CAR-NK, tumor vaccine, oncolytic virus vaccine, TLR7/8 agonist, anti-CD47 or IL-2 receptor agonist and optionally also including other pharmacologically immune-boosting active agents.